ALEXANDRIA, Va., Nov. 6 -- United States Patent no. 12,458,696, issued on Nov. 4, was assigned to Replimune Ltd. (Oxfordshire, Great Britain).
"Modified oncolytic virus" was invented by Robert Coffin (London).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to an oncolytic virus comprising: (i) a fusogenic protein-encoding gene; and (ii) an immune stimulatory molecule-encoding gene."
The patent was filed on Aug. 3, 2022, under Application No. 17/817,245.
*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=12458696&OS=...